The purpose of this study is to evaluate patients with cirrhosis of the liver and renal
failure and determine if the administration of rifaximin as compared to lactulose is
associated with less frequent and/or slower progression to severe hepatic encephalopathy. If
one is associated with lower blood ammonia levels. And, if one is associated with lower
breath hydrogen and methane levels.